Document is current
Any future updates will be listed below
-
Authors
Rao, Shalini V.
Young, Lisa
Cheeseman, Danya
Flynn, Sean
Krebs, Niklas
Couturier, Dominique-Laurent https://orcid.org/0000-0001-5774-5036
Mack, Stephanie
Brais, Rebecca
Temple, Jill
Smith, Amy
Papachristou, Evangelia https://orcid.org/0000-0002-5835-2055
Pelicano, Catarina https://orcid.org/0000-0002-7039-2922
Chilamakuri, Chandra Sekhar Reddy
Herka, Krzysztof
Baba, Hideo
Farah, Luay
Cheung, Phyllis F.
Siveke, Jens
Guerrier, Stéphane
Insolia, Luca https://orcid.org/0000-0003-4169-5446
Gill, Michael
Archer Goode, Emily
Kupczak, Steven
Cheng, Yi
Borsari, Giacomo https://orcid.org/0000-0002-0584-5737
Jodrell, Duncan https://orcid.org/0000-0001-9360-1670
D’Santos, Clive
Russell, Alasdair
Grünwald, Barbara T.
Serrao, Eva
Chernukhin, Igor
Carroll, Jason S. https://orcid.org/0000-0003-3643-0080
-
Funding
Funding for this research was provided by:
Cancer Research UK (G101107)
Pancreatic Cancer UK (G109884)
Pancreatic Cancer UK (G109884)
- License Information
-
More Information
Article History
Received: 17 February 2024
Accepted: 25 September 2025
First Online: 30 October 2025
Competing interests
: J.S.C. has received past research funding from AstraZeneca, which is unrelated to this work. J.S. receives honoraria as a consultant or for continuing medical education presentations from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Immunocore, MSD, Novartis, Roche/Genentech and Servier. His institution receives research funding from Abalos Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eisbach Bio and Roche/Genentech; he holds ownership in FAPI Holding (3%); all are unrelated to the submitted work.
